JP5981141B2 - 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用 - Google Patents
多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用 Download PDFInfo
- Publication number
- JP5981141B2 JP5981141B2 JP2011545498A JP2011545498A JP5981141B2 JP 5981141 B2 JP5981141 B2 JP 5981141B2 JP 2011545498 A JP2011545498 A JP 2011545498A JP 2011545498 A JP2011545498 A JP 2011545498A JP 5981141 B2 JP5981141 B2 JP 5981141B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- multiple organ
- subject
- organ dysfunction
- mods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
例1:ヒトおよびマウスIL−22遺伝子のクローニング
Claims (13)
- IL−22を含む、対象における多臓器不全症候群を処置するための医薬組成物。
- IL−22が、多臓器不全症候群を患う対象において、血清総タンパク質を増加させる、請求項1に記載の医薬組成物。
- IL−22が、多臓器不全症候群を患う対象において、血清アルブミンを増加させる、請求項1に記載の医薬組成物。
- IL−22が哺乳動物のIL−22である、請求項1に記載の医薬組成物。
- IL−22が、組み換え型の哺乳動物のIL−22である、請求項1に記載の医薬組成物。
- IL−22の薬学的有効量が、1日につき対象キログラムあたり100〜1000マイクログラムの範囲である、請求項1に記載の医薬組成物。
- IL−22を含む、対象における全身性炎症反応症候群を処置するための医薬組成物。
- IL−22が対象における生存率を増加させる、請求項7に記載の医薬組成物。
- IL−22が哺乳動物のIL−22である、請求項7に記載の医薬組成物。
- IL−22が、組み換え型の哺乳動物のIL−22である、請求項7に記載の医薬組成物。
- IL−22の薬学的有効量が、1日につき対象キログラムあたり100〜500マイクログラムの範囲である、請求項7に記載の医薬組成物。
- 多臓器不全症候群が、敗血症によって生じる、請求項1に記載の医薬組成物。
- 多臓器不全症候群が、エンドトキシン誘導の敗血症によって生じる、請求項12に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14413409P | 2009-01-12 | 2009-01-12 | |
US61/144,134 | 2009-01-12 | ||
PCT/US2010/020673 WO2010081112A1 (en) | 2009-01-12 | 2010-01-11 | Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012515165A JP2012515165A (ja) | 2012-07-05 |
JP2012515165A5 JP2012515165A5 (ja) | 2013-02-28 |
JP5981141B2 true JP5981141B2 (ja) | 2016-08-31 |
Family
ID=42316862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011545498A Active JP5981141B2 (ja) | 2009-01-12 | 2010-01-11 | 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8956605B2 (ja) |
EP (1) | EP2385841B1 (ja) |
JP (1) | JP5981141B2 (ja) |
CN (1) | CN102348463B (ja) |
AU (1) | AU2010203446B2 (ja) |
CA (1) | CA2748392C (ja) |
WO (1) | WO2010081112A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
TR201809571T4 (tr) | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
CN112007146A (zh) * | 2020-09-03 | 2020-12-01 | 上海市儿童医院 | Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途 |
US20240033232A1 (en) * | 2021-03-10 | 2024-02-01 | Wen Tan | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1082433A4 (en) * | 1998-05-29 | 2003-01-02 | Human Genome Sciences Inc | Interleukins 21 and 22 |
US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
US7226591B2 (en) * | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
CN100515491C (zh) * | 2005-01-04 | 2009-07-22 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
CN101219208B (zh) * | 2005-01-04 | 2010-08-11 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
US20080031882A1 (en) * | 2006-06-19 | 2008-02-07 | Liang Spencer C | Methods of modulating IL-22 and IL-17 |
WO2008085229A2 (en) * | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
CN101168049A (zh) * | 2007-10-23 | 2008-04-30 | 中国人民解放军军事医学科学院基础医学研究所 | 白介素-22在制备治疗肝病药物中的应用及其制备方法 |
-
2010
- 2010-01-11 US US13/142,423 patent/US8956605B2/en active Active
- 2010-01-11 CN CN201080010768.7A patent/CN102348463B/zh active Active
- 2010-01-11 JP JP2011545498A patent/JP5981141B2/ja active Active
- 2010-01-11 CA CA2748392A patent/CA2748392C/en active Active
- 2010-01-11 WO PCT/US2010/020673 patent/WO2010081112A1/en active Application Filing
- 2010-01-11 AU AU2010203446A patent/AU2010203446B2/en active Active
- 2010-01-11 EP EP10729641.0A patent/EP2385841B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2010203446B2 (en) | 2015-12-17 |
CA2748392A1 (en) | 2010-07-15 |
EP2385841A4 (en) | 2012-12-19 |
CA2748392C (en) | 2017-06-27 |
WO2010081112A1 (en) | 2010-07-15 |
AU2010203446A1 (en) | 2011-07-14 |
EP2385841B1 (en) | 2016-11-16 |
CN102348463A (zh) | 2012-02-08 |
CN102348463B (zh) | 2014-05-07 |
US8956605B2 (en) | 2015-02-17 |
US20110268696A1 (en) | 2011-11-03 |
EP2385841A1 (en) | 2011-11-16 |
JP2012515165A (ja) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5981141B2 (ja) | 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用 | |
US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
KR101873773B1 (ko) | 류마티즘 관절염 예방 또는 치료 조성물 | |
WO2000051623A2 (en) | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions | |
HU229045B1 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
JP2023134616A (ja) | 炎症性腸疾患の治療薬 | |
RU2627451C9 (ru) | Противовоспалительные композиции | |
JP6023803B2 (ja) | 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ | |
JP7163547B2 (ja) | 新規ペプチドおよびその用途 | |
TW201302214A (zh) | 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物 | |
US20060094679A1 (en) | Method of preventing or treating liver disease | |
AU2008226337B2 (en) | Method for treating cancer via the mucosal administration of interleukin | |
JP4023863B2 (ja) | Il−6を含む血清尿酸値低下剤 | |
AU2007226130B2 (en) | Use of caspases for the preparation of medicaments | |
CN108853483B (zh) | 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途 | |
RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью | |
JP2012504941A5 (ja) | ||
US10517928B2 (en) | Pharmaceutical composition for treating and/or preventing esophageal stenosis | |
CN118236470A (zh) | MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用 | |
JP2001151692A (ja) | イヌパルボウイルス感染症治療方法および治療剤 | |
MXPA01012663A (es) | Uso de interleucina-11 para tratar el shock hemorragico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130109 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140428 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140528 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160728 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5981141 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |